HEALTHFOX NEWS POLITICS
FDA delays cost Americans trillions and slow lifesaving drugs, new report says
A new report claims that accelerating FDA drug approvals could generate over $10 trillion in economic value by reducing delays in effectiveness trials, which currently take about a decade. The report suggests reforms like AI in reviews and faster trials to boost competition and lower drug costs, while also addressing China's competitive threat in clinical trials.
Mentioned
Related Signal
Adjacent reporting
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says
- Trump's drugmaker deals may save economy $529B over 10 years, White House says
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- Trump-backed plan could fast-track psychedelic therapies — here’s what to know